Global AI In Respiratory Diseases Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

AI in Respiratory Diseases Market Size

• The global AI in respiratory diseases market size was valued at USD 9.10 billion in 2024 and is expected to reach USD 83.37 billion by 2032, at a CAGR of 31.90% during the forecast period
• The market growth is largely fueled by the increasing prevalence of respiratory disorders such as COPD, asthma, and lung infections, coupled with the need for early detection, accurate diagnostics, and personalized treatment planning powered by artificial intelligence
• Furthermore, rising demand for efficient clinical decision support tools, integration of AI in imaging and predictive analytics, and growing adoption of digital health technologies in respiratory care settings are establishing AI as a transformative force in pulmonary medicine. These converging factors are accelerating the integration of AI in respiratory disease management, thereby significantly boosting the industry's growth

AI in Respiratory Diseases Market Analysis

• AI in respiratory diseases, encompassing advanced tools for imaging, diagnostics, and clinical decision support, is becoming an essential component of modern respiratory care across hospitals, diagnostic centers, and research institutions due to its ability to enhance diagnostic precision, predict disease progression, and support personalized treatment strategies
• The accelerating demand for AI in this field is primarily fueled by the rising global burden of chronic respiratory illnesses such as COPD and pulmonary infections, growing need for early and accurate detection, and increasing integration of AI in medical imaging and digital health platforms
• North America dominated the AI in respiratory diseases market with the largest revenue share of 45.1% in 2024, attributed to its advanced healthcare infrastructure, widespread use of digital health technologies, and robust investments in AI research, particularly across the U.S., where healthcare providers are increasingly adopting AI-driven imaging tools and predictive models
• Asia-Pacific is expected to be the fastest growing region during the forecast period, driven by improving healthcare access, rising healthcare expenditures, and government support for AI integration in clinical settings
• The CT scan segment dominated the AI in respiratory diseases market with a market share of 31.6% in 2024, owing to its central role in detecting and monitoring respiratory conditions, and the integration of AI algorithms for image analysis, disease quantification, and diagnostic support

Report Scope and AI in Respiratory Diseases Market Segmentation 

AI in Respiratory Diseases Market Trends

“Enhanced Diagnostics and Decision Support Through AI Integration”

• A significant and rapidly advancing trend in the global AI in respiratory diseases market is the growing integration of artificial intelligence into diagnostic imaging, clinical decision support, and patient monitoring tools. This development is revolutionizing pulmonary care by enabling earlier detection, improved diagnostic accuracy, and personalized treatment planning
  • For instance, AI-enhanced CT and X-ray analysis platforms such as those by Zebra Medical Vision and Aidoc are capable of automatically detecting abnormalities such as nodules, fibrosis, and inflammation—often before symptoms manifest—enabling more proactive disease management
• AI is also being applied to predict patient deterioration in real time. Solutions such as those from Tempus and Qure.ai use machine learning to analyze patterns in respiratory data and imaging to guide clinician interventions. In electronic patient-reported outcomes (ePRO) platforms, AI algorithms are used to monitor patient inputs and flag potential exacerbations or complications in conditions such as COPD and ILD
• Furthermore, the integration of AI with hospital information systems and telemedicine platforms allows clinicians to access consolidated views of imaging, pulmonary function tests, and predictive insights, streamlining workflows and enhancing decision-making
• As AI tools become more interoperable with existing radiology and EMR systems, their adoption is accelerating in both urban and rural healthcare settings. Companies such as GE HealthCare and Siemens Healthineers are developing AI-powered respiratory diagnostics with cloud-based deployment options, expanding accessibility across geographies
• This trend toward intelligent, predictive, and integrated respiratory care systems is reshaping expectations in clinical pulmonology. Consequently, stakeholders in both healthcare and technology sectors are investing heavily in AI-based solutions that support early intervention and improved patient outcomes across various respiratory diseases

AI in Respiratory Diseases Market Dynamics

Driver

“Rising Respiratory Disease Burden and Need for Early, Accurate Diagnosis”

• The global rise in respiratory conditions such as chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and lung infections is a major factor driving the AI in respiratory diseases market. These conditions are increasingly being detected and managed using AI tools that enhance imaging interpretation, identify subtle patterns, and reduce diagnostic delays
  • For instance, in 2024, Qure.ai launched an updated version of its AI-based chest X-ray screening tool, capable of detecting 30+ findings including tuberculosis and pneumonia, aimed at improving diagnosis in resource-limited settings. Such innovations are expanding access to quality diagnostics across underserved populations
• The growing need for efficient clinical decision-making, especially amid shortages of radiologists and pulmonologists, is also fueling demand for AI-based respiratory tools. These systems help reduce interpretation times, minimize diagnostic errors, and guide treatment with data-backed insights
• In addition, the rise of telemedicine and digital health platforms during and after the COVID-19 pandemic has accelerated the integration of AI in remote respiratory monitoring, allowing continuous evaluation of patient symptoms, lung function, and disease progression
• AI’s ability to process multimodal data combining imaging, patient history, and biomarkers enables comprehensive assessments that support clinicians in tailoring therapies and tracking treatment efficacy. This holistic approach is increasingly valued in personalized respiratory medicine, particularly in high-burden conditions such as COPD and asthma

Restraint/Challenge

“Data Privacy Concerns and Regulatory Barriers”

• Despite the benefits, challenges such as data privacy concerns and regulatory compliance hurdles pose significant limitations to AI adoption in respiratory care. AI systems require access to vast amounts of patient data—imaging, clinical records, and biosignals—which raises issues around confidentiality, consent, and data ownership
  • For instance, healthcare institutions must comply with stringent data protection regulations such as HIPAA in the U.S. and GDPR in the EU, making it complex to integrate AI solutions across borders or within multi-institutional networks
• In addition, the regulatory approval process for AI-based medical devices remains lengthy and complex, with many countries lacking clear, unified frameworks. This can delay time-to-market and limit real-world application, especially for start-ups and smaller developers
• Another challenge lies in the variability and bias within training datasets used for developing AI models. Poor data diversity may lead to reduced accuracy when applied to different populations, risking misdiagnosis
• Overcoming these barriers will require stronger international standards for AI validation, better data governance policies, and continued collaboration between regulators, clinicians, and technology developers to ensure ethical and equitable implementation

AI in Respiratory Diseases Market Scope

The market is segmented on the basis of indication, imaging type, and end-use.

• By Indication

On the basis of indication, the AI in respiratory diseases market is segmented into chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and pulmonary infection. The chronic obstructive pulmonary disease (COPD) segment dominated the market with the largest market revenue share in 2024, driven by the rising global prevalence of the disease and the increasing use of AI tools for early diagnosis, risk stratification, and disease progression monitoring. AI-enabled systems in COPD care support clinicians by offering predictive analytics, personalized treatment recommendations, and enhanced imaging interpretations.

The interstitial lung disease (ILD) segment is anticipated to witness the fastest growth rate from 2025 to 2032, owing to the diagnostic complexity and growing demand for high-resolution imaging solutions. AI’s ability to differentiate among ILD subtypes and quantify fibrosis makes it especially valuable in improving diagnostic accuracy and patient outcomes.

• By Imaging Type

On the basis of imaging type, the AI in respiratory diseases market is segmented into CT Scan, MRI, and ePRO (electronic Patient-Reported Outcomes). The CT Scan segment held the largest market revenue share of 31.6% in 2024, driven by its widespread use in detecting pulmonary abnormalities and the seamless integration of AI algorithms for image analysis and disease quantification. CT imaging remains the gold standard for evaluating lung diseases, and AI enhances its utility by automating findings and reducing interpretation times.

The ePRO segment is expected to witness the fastest growth rate from 2025 to 2032, driven by the rising adoption of remote monitoring platforms and AI-powered analytics that transform patient-reported data into real-time clinical insights. ePRO platforms are increasingly used in chronic disease management, allowing early detection of symptom exacerbations and improved patient engagement

• By End-use

On the basis of end-use, the AI in respiratory diseases market is segmented into hospitals, diagnostic centers, ambulatory surgical centers, and others. The Hospitals segment dominated the market with the largest market revenue share of 64.8% in 2024, attributed to the presence of advanced diagnostic infrastructure, large patient volumes, and growing adoption of AI-based imaging and decision-support systems. Hospitals are leading adopters of AI for real-time respiratory monitoring, integrated clinical workflows, and enhanced diagnostic accuracy.

The Diagnostic Centers segment is expected to grow steadily during the forecast period due to increasing demand for efficient and cost-effective imaging services supported by AI tools. These centers benefit from AI’s capability to automate interpretations and reduce turnaround times, especially in high-volume environments.

AI in Respiratory Diseases Market Regional Analysis

• North America dominated the AI in respiratory diseases market with the largest revenue share of 45.1% in 2024, attributed to its advanced healthcare infrastructure, widespread use of digital health technologies, and robust investments in AI research
• The region’s leadership is further supported by strong investments in AI research, widespread integration of digital health platforms, and increasing reliance on AI-driven imaging and decision-support tools in clinical settings
• The U.S., in particular, is at the forefront of this adoption due to its large base of AI healthtech companies, proactive regulatory support for AI-enabled diagnostics, and growing emphasis on early, data-driven respiratory disease management, solidifying North America’s position as the dominant market for AI in respiratory care

U.S. AI in Respiratory Diseases Market Insight

The U.S. AI in respiratory diseases market captured the largest revenue share of 78.3% in 2024 within North America, driven by early adoption of AI in healthcare, strong digital infrastructure, and the rising burden of chronic respiratory conditions. The integration of AI algorithms into diagnostic imaging, patient monitoring, and electronic health records is significantly improving clinical outcomes. Moreover, supportive regulatory frameworks and increased funding for AI-driven healthcare innovations are further propelling the market in the U.S., making it a hub for advanced respiratory diagnostics and management solutions.

Europe AI in Respiratory Diseases Market Insight

The Europe AI in respiratory diseases market is projected to expand at a substantial CAGR throughout the forecast period, fueled by increasing government support for AI technologies and a growing focus on precision medicine. The region is witnessing accelerated adoption of AI-enabled tools across hospitals and diagnostic centers to enhance early detection and treatment of lung diseases. Countries such as Germany, France, and the U.K. are investing heavily in digital health initiatives, supporting the integration of AI in radiology and pulmonary diagnostics.

U.K. AI in Respiratory Diseases Market Insight

The U.K. AI in respiratory diseases market is anticipated to grow at a noteworthy CAGR during the forecast period, backed by a national strategy to leverage AI in healthcare and the NHS’s digital transformation goals. The country’s focus on reducing respiratory-related morbidity through early diagnosis and data-driven care is driving the adoption of AI tools. Moreover, growing collaborations between health tech startups and research institutions are supporting the development of AI-based respiratory solutions tailored to local healthcare needs.

Germany AI in Respiratory Diseases Market Insight

The Germany AI in respiratory diseases market is expected to expand at a considerable CAGR during the forecast period, driven by strong investments in digital health and increasing demand for advanced diagnostic tools. Germany’s focus on integrating AI into hospital workflows and its robust regulatory environment support the adoption of AI-based respiratory analysis systems. In addition, rising awareness of pulmonary conditions and the push toward efficient, automated diagnostic models are boosting the market.

Asia-Pacific AI in Respiratory Diseases Market Insight

The Asia-Pacific AI in respiratory diseases market is poised to grow at the fastest CAGR of 25.6% during the forecast period of 2025 to 2032, fueled by rising healthcare digitalization, an increasing patient population with respiratory diseases, and technological advancement in countries such as China, Japan, and India. Regional governments are emphasizing AI integration in healthcare delivery to enhance diagnostic accuracy and patient outcomes. The affordability of AI platforms and increasing research partnerships are also encouraging widespread adoption.

Japan AI in Respiratory Diseases Market Insight

The Japan AI in respiratory diseases market is gaining momentum due to the country's strong technology base, aging population, and high incidence of chronic lung diseases. Hospitals and diagnostic centers are increasingly deploying AI-powered imaging tools and predictive analytics to manage and monitor respiratory conditions. The government's commitment to AI-driven healthcare innovation and the rise in telehealth services are supporting market growth.

India AI in Respiratory Diseases Market Insight

The India AI in respiratory diseases market accounted for the largest market revenue share in Asia Pacific in 2024, driven by the surge in digital health startups, increasing respiratory disease burden, and government initiatives promoting AI in public healthcare. The country’s rapidly expanding healthcare infrastructure, coupled with the adoption of AI for low-cost, scalable screening solutions, is enhancing early diagnosis in both urban and rural populations. Strategic collaborations between AI firms and healthcare providers are further accelerating market penetration.

AI in Respiratory Diseases Market Share

The AI in respiratory diseases industry is primarily led by well-established companies, including:

• GE HealthCare (U.S.)
• Siemens Healthineers AG (Germany)
• Koninklijke Philips N.V. (Netherlands)
• Aidoc Medical Ltd. (Israel)
• Zebra Medical Vision Ltd. (Israel)
• Qure.ai Technologies Pvt. Ltd. (India)
• Fujifilm Holdings Corporation (Japan)
• Canon Medical Systems Corporation (Japan)
• Bayer AG (Germany)
• RadNet, Inc. (U.S.)
• Enlitic, Inc. (U.S.)
• NVIDIA Corporation (U.S.)
• Lunit Inc. (South Korea)
• HeartVista, Inc. (U.S.)
• Infervision Medical Technology Co., Ltd. (China)
• VUNO Inc. (South Korea)
• iCAD, Inc. (U.S.)
• Perspectum Ltd. (U.K.)
• Arterys Inc. (U.S.)

What are the Recent Developments in Global AI in Respiratory Diseases Market?

• In April 2023, GE HealthCare Technologies Inc. launched its updated AI-powered Thoracic Care Suite, designed to assist clinicians in detecting and managing pulmonary diseases, including pneumonia and chronic obstructive pulmonary disease (COPD). Integrated within X-ray imaging systems, this solution leverages advanced algorithms to identify critical findings quickly, thereby enhancing diagnostic accuracy and workflow efficiency. This innovation underscores GE HealthCare’s commitment to revolutionizing respiratory diagnostics through AI-driven radiology tools
• In March 2023, Siemens Healthineers collaborated with the European Respiratory Society (ERS) to pilot an AI-based respiratory screening platform that integrates imaging, spirometry, and patient-reported data. The platform aims to improve early detection and monitoring of interstitial lung diseases (ILD) by utilizing predictive analytics. This development highlights Siemens’ strategic focus on interdisciplinary AI solutions tailored for chronic respiratory care across Europe
• In March 2023, Zebra Medical Vision (now part of Nanox) received regulatory clearance for its AI-powered pulmonary imaging algorithm in Japan. The software assists radiologists by automatically identifying signs of emphysema and other lung abnormalities in chest CT scans. This milestone reflects the growing adoption of AI in diagnostic imaging across Asia, contributing to faster, more accurate respiratory disease assessments
• In February 2023, Qure.ai announced the integration of its AI algorithm, qXR, with portable X-ray devices deployed in Indian rural healthcare centers under a government-led lung health initiative. The AI model enables frontline health workers to detect signs of tuberculosis and other respiratory illnesses in real time, facilitating early intervention. This advancement demonstrates Qure.ai’s dedication to improving respiratory care accessibility and outcomes in underserved regions through scalable AI solutions
• In January 2023, Aidoc, a leading AI radiology company, introduced a new suite of AI-based triage tools for emergency care settings, specifically designed to identify acute pulmonary embolisms and other critical lung conditions. By providing real-time alerts and decision support to clinicians, Aidoc aims to reduce diagnostic delays and improve patient outcomes in high-pressure environments. This release reinforces the role of AI in enhancing emergency respiratory diagnostics and streamlining clinical workflows

SKU-70339